714 related articles for article (PubMed ID: 29426921)
41. [Myeloproliferative neoplasms: pathophysiology and therapeutic strategy].
Kubuki Y; Hidaka T; Shimoda K
Rinsho Ketsueki; 2015 Oct; 56(10):1996-2004. PubMed ID: 26458438
[TBL] [Abstract][Full Text] [Related]
42. Recent advances in understanding myelofibrosis and essential thrombocythemia.
Vainchenker W; Constantinescu SN; Plo I
F1000Res; 2016; 5():. PubMed ID: 27134742
[TBL] [Abstract][Full Text] [Related]
43. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
44. [Research progress of myeloproliferative neoplasms].
He HJ; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):278-84. PubMed ID: 25687088
[TBL] [Abstract][Full Text] [Related]
45. The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.
Thiele J; Kvasnicka HM; Orazi A; Gianelli U; Gangat N; Vannucchi AM; Barbui T; Arber DA; Tefferi A
Am J Hematol; 2023 Jan; 98(1):166-179. PubMed ID: 36200127
[TBL] [Abstract][Full Text] [Related]
46. Deactylase inhibition in myeloproliferative neoplasms.
Mithraprabhu S; Grigoriadis G; Khong T; Spencer A
Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S50-7. PubMed ID: 21127942
[TBL] [Abstract][Full Text] [Related]
47. [Current diagnosis of myeloproliferative neoplasms (2008 WHO classification)].
Frenkel' MA
Klin Lab Diagn; 2011 Jan; (1):43-9. PubMed ID: 21433318
[TBL] [Abstract][Full Text] [Related]
48. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
Koopmans SM; Schouten HC; van Marion AM
Histol Histopathol; 2015 Feb; 30(2):151-61. PubMed ID: 25196073
[TBL] [Abstract][Full Text] [Related]
49. WHO classification of myeloproliferative neoplasms (MPN): A critical update.
Kvasnicka HM
Curr Hematol Malig Rep; 2013 Dec; 8(4):333-41. PubMed ID: 24146204
[TBL] [Abstract][Full Text] [Related]
50. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
51. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
52. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
[TBL] [Abstract][Full Text] [Related]
53. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
54. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
Vardiman JW; Thiele J; Arber DA; Brunning RD; Borowitz MJ; Porwit A; Harris NL; Le Beau MM; Hellström-Lindberg E; Tefferi A; Bloomfield CD
Blood; 2009 Jul; 114(5):937-51. PubMed ID: 19357394
[TBL] [Abstract][Full Text] [Related]
55. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
56. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.
Tefferi A
Leuk Lymphoma; 2010 Apr; 51(4):576-82. PubMed ID: 20214447
[TBL] [Abstract][Full Text] [Related]
57. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
58. GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.
Yang N; Park S; Cho MS; Lee M; Hong KS; Mun YC; Seong CM; Huh HJ; Huh J
Ann Lab Med; 2018 Jul; 38(4):296-305. PubMed ID: 29611379
[TBL] [Abstract][Full Text] [Related]
59. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
60. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants.
Vardiman J; Hyjek E
Hematology Am Soc Hematol Educ Program; 2011; 2011():250-6. PubMed ID: 22160042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]